Maggie L. Shaw

2 weeks ago | ajmc.com | Maggie L. Shaw

Even with more than 16 million instances of contact since it launched across the US in July 2022, with almost half of these contacts (8,050,380; 49.3%) coming in 2024 alone, lifetime use of the 988 suicide and crisis lifeline came in at less-than-expected levels for the year ending December 2024.

3 weeks ago | ajmc.com | Maggie L. Shaw

New data were recently published showing that SHR0302, better known as ivarmacitinib, is safe and effective to use in adolescent and adult patients against atopic dermatitis, the most common chronic inflammatory subtype of eczema—specifically, moderate to severe disease.

3 weeks ago | ajmc.com | Maggie L. Shaw |Jaime P. Almandoz

In this second half of a recent interview on trends in tirzepatide use, Jaime Almandoz, MD, MBA, calls for scalable, team-based care models to support the growing use of obesity medications like tirzepatide. Integrating pharmacotherapy with nutrition, behavioral health, and surgery is essential—but so is equitable, sustained access. Almandoz stresses the need for better training in access navigation.

3 weeks ago | ajmc.com | Maggie L. Shaw

With data from 1985 to 2025 showing cases of type 1 diabetes on the rise globally, and that incidence of the chronic autoimmune disease is disproportionately higher among persons from lower-income countries, experts of a new study in Diabetes Research and Clinical Practice highlight the importance of new epidemiological studies for inroads to care.1 The authors propose that the higher numbers could be due to an increase in incidence stemming from a population growth, aging, or a decrease in...

3 weeks ago | ajmc.com | Maggie L. Shaw |Anjali Vaidya

At the 2025 American Thoracic Society International Conference, Anjali Vaidya, MD, FACC, FASE, FACP, co-director of the Advanced Pulmonary Hypertension, Right Heart Failure & CTEPH Program at Temple University Hospital, presented the poster, “Qualitative Interviews of Patients with Meth-PAH: Understanding the Unmet Medical Need from the Patient Lens.” The study involved interviews with patients across the US diagnosed with methamphetamine-associated pulmonary arterial hypertension (meth-PAH).